The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2025 | The new era of imaging in myeloma: combining 3 T whole-body MRI and 18F-FDG PET/CT
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the new era of imaging in myeloma, combining 3 T whole-body MRI and 18F-FDG PET/CT. Dr Cerchione believes that this approach will become the standard, particularly when combined with molecular data, ultimately aiming to improve patient outcomes. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The revolution in multiple myeloma is going to continue and particularly we are going to concentrate not only on disease control but also on improving the diagnosis and monitoring of our patients. Particularly in our institution we have evaluated all the consecutive patients coming for smoldering myeloma, newly diagnosed myeloma, or relapsed/refractory myeloma, with the combination of the new best techniques that we have available in the diagnosis of multiple myeloma...
The revolution in multiple myeloma is going to continue and particularly we are going to concentrate not only on disease control but also on improving the diagnosis and monitoring of our patients. Particularly in our institution we have evaluated all the consecutive patients coming for smoldering myeloma, newly diagnosed myeloma, or relapsed/refractory myeloma, with the combination of the new best techniques that we have available in the diagnosis of multiple myeloma. Full body MRI, 3TESLA together with PET-CT. And we have seen that the combination of two methods is really important not only to discriminate between lesions in which in some way we have some confusion, but particularly to change the management in a big number of patients, 60%. In these patients, it has changed the management in terms of anticipating a treatment in smoldering myeloma or switching to another treatment in relapsed/refractory multiple myeloma. And this is particularly important because this helps to optimize the cost of the drug, the toxicity of the drug and also the outcome of our patients because in some way we can anticipate the treatment according to a result of an imaging evaluation and I think that in the next future the combination will be the best that we can offer to our patients, in particular if we go to combine this data with other new generation evaluations such as the molecular data that we have shown in another poster I think that the future of multiple myeloma will be to concentrate not only on effectiveness of new drugs, but to improve all what we have learned in these years, particularly also about the imaging techniques. And this will help us to cure and eradicate multiple myeloma. This is the best wish that we give to our patients, to all caregivers, and to all the researchers that fight every day against multiple myeloma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Advisory board and/or Consultant and/or speaker for Abbvie, AMGEN, Astellas, Beigene, BMS, Curis, Glycomimetics, GSK, Immunogen, Janssen, Jazz, Karyopharm, Menarini – Stemline, Oncopeptides, Pfizer, Sanofi, Servier, Skyline DX, Stemline, Takeda.
